

12 WEEK FINAL ANALYSIS

January 2012

JoAnne Watson, D.P.M. Associate Director Clinical Affairs

Barbara Coffey, Project Coordinator



obagí for life

#### MAIN INCLUSION CRITERIA

- Male or Female subjects between the ages of 12 through 25 years of age (inclusive);
- Mild to moderate facial acne (excluding the nose), with normal skin: 17 to 40 inflammatory (papules, pustules, and nodules), 10 to 100 non-inflammatory (open and closed comedones), up to 2 nodulo-cystic lesions may be present;
- A Physician's Global Assessment of mild to moderate (2 – 3)



obagí for life

#### **DEMOGRAPHICS**

N	22*
Gender Male (%)	68%
Gender Female (%)	32%
Age (Mean)	15.6
White/Caucasian (%)	81%
Black/African American (%)	5%
American Indian/Alaska Native (%)	5%
Caucasian & Asian (%)	9%

<sup>\*</sup> All 22 subjects enrolled completed study



obagí for life

#### STUDY TREATMENT REGIMEN

Optimized CLENZIderm M.D.™ System			
AM	PM (evening prior to bedtime)		
Daily Care Foaming Cleanser (2% salicylic acid)	Daily Care Foaming Cleanser (2% salicylic acid)		
	Pore Therapy (2% salicylic acid)		
	Therapeutic Lotion (5% BPO)		

CLENZIderm M.D.™ Therapeutic Moisturizer was provided if needed for dryness or other tolerability symptoms. Nu-Derm® Healthy Skin Protection SPF 35 sunscreen was provided to use if exposed to sun.



obagí for life

#### **EFFICACY**



obagí for life


- Non-Inflammatory Lesions = Open and Closed Comedones
- Inflammatory Lesions = Papules, Pustules and Nodules
- Total Lesions = Non-Inflammatory and Inflammatory Lesions

#### **Lesion Definitions**

- Open Comedone Non-inflamed partially plugged hair follicle with dilated/open orifice with a black surface
- Closed Comedone Non-inflamed partially plugged hair follicle with a closed orifice, white in color
- Papule A solid, elevated inflammatory lesion less than 0.5 cm
- **Pustule** An elevated inflammatory lesion less than 0.5 cm, contains pus
- Nodule/Cyst Palpable solid inflammatory lesion, greater than 0.5 cm, has depth, not necessarily elevated




obagí for life



obagí for life

#### LESION COUNTS – NON-INFLAMMATORY LESIONS % CHANGE FROM BASELINE




Statistically significant reduction lesions all visits

\* p ≤ 0.01 vs. Baseline




Mean % Change

obagi for life



obagí for life

#### TOTAL INFLAMMATORY LESION COUNT




\* p ≤ 0.01 vs. Baseline



obagí for life

#### TOTAL NON-INFLAMMATORY LESION COUNT




\* p ≤ 0.01 vs. Baseline



obagí for life

#### **TOTAL LESION COUNT**

(NON-INFLAMMATORY & INFLAMMATORY COMBINED)



\* p ≤ 0.01 vs. Baseline



obagí for life


#### PHYSICIAN GLOBAL ASSESSMENT SCALE

0 - Clear	Normal, clear skin with no evidence of acne vulgaris	
1 - Almost Clear	l inflamed papules (papules must be resolving and may be hyperpigmented	
2 - Mild	2 - Mild  Some non-inflammatory lesions are present, with few inflammatory lesion (papules/pustules only; no nodulo-cystic lesions)	
3 - Moderate	Non-inflammatory lesions predominate, with multiple inflammatory lesions evident: several to many comedones and papules/pustules, up to two nodulo-cystic lesions may be present	
4 - Severe	Inflammatory lesions are more apparent: many comedones and papules/pustules; there may or may not be a few nodulo-cystic lesions	
5 - Very Severe	Highly inflammatory lesions predominate: variable number of comedones, many papules/pustules nodulo-cystic lesions	



obagí for life

#### PHYSICIAN GLOBAL ASSESSMENT





obagí for life

#### **TOLERABILITY**



obagí for life


#### **TOLERABILITY - ERYTHEMA**

0	None – no erythema present (may be minor discoloration)	
1	Mild – light pink, noticeable	
2	Moderate – pink-red, easily noticeable	
3	Severe – deep or bright red, may be warm to the touch	



obagí for life


#### **TOLERABILITY - ERYTHEMA**





#### **TOLERABILITY ASSESSMENTS BY VISIT**










#### **TOLERABILITY - DRYNESS**

0	None – no dryness present
1	Mild – slight but definite roughness
2	Moderate – moderate roughness
3	Severe – marked roughness



obagí for life


#### **TOLERABILITY - DRYNESS**





obagí for life

#### **TOLERABILITY ASSESSMENTS BY VISIT**



(Day 28 1 Subject Severe Dryness)



**Dryness** 

obagí for life


#### **TOLERABILITY - PEELING**

0	None – no peeling present
1	Mild – slight peeling
2	Moderate – definitely noticeable peeling
3	Severe – extensive peeling



obagí for life


#### **TOLERABILITY - PEELING**





obagí for life


#### **TOLERABILITY ASSESSMENTS BY VISIT**



(Day 28 1 Subject Severe Dryness)



Peeling




#### **TOLERABILITY - STINGING/BURNING**

0	None – no stinging/burning
1	Mild – light warm, tingling sensation, not really bothersome
2	Moderate – definite warmth, tingling/stinging sensation that is somewhat bothersome
3	Severe – hot tingling/stinging sensation which is disturbing normal activity



obagí for life

#### **TOLERABILITY - STINGING/BURNING**






# Stinging/Burning

### CLZ-003 OPTIMIZED CLENZIDERM M.D. MILD TO MODERATE FACIAL ACNE VULGARIS

obagí for life

#### TOLERABILITY ASSESSMENTS BY VISIT





obagí for life


#### **TOLERABILITY – ITCHING**

0	None – no itching
1	Mild – occasional, slight itching
2	Moderate – constant or intermittent itching that is somewhat bothersome
3	Severe – bothersome itching which is disturbing normal activity



obagí for life


#### **TOLERABILITY - ITCHING**





obagí for life

#### **TOLERABILITY ASSESSMENTS BY VISIT**






Itching

obagí for lífe

#### SUBJECT QUESTIONNAIRES





#### TREATMENT RELATED ADVERSE EVENTS

ADVERSE EVENT DESCRIPTION	AE INTENSITY	TOTAL # SUBJECTS
Facial Dryness and Peeling*	Severe	1




<sup>\*</sup> Rated by Investigator, no treatment required by subject

obagí for life

#### SUBJECT SELF-ASSESSED ACNE IMPROVEMENT


(Good, Very Good & Excellent)





obagí for life

#### SUBJECT SELF-ASSESSED ACNE IMPROVEMENT






obagí for life

#### SUBJECT SELF-ASSESSED SATISFACTION OF ACNE IMPROVEMENT


(Satisfied + Very Satisfied)






obagí for life

#### SUBJECT SELF-ASSESSED SATISFACTION OF ACNE IMPROVEMENT






obagí for life





obagí for life


#### SUBJECT SELF-ASSESSED EFFECTIVENESS OF TREATMENT PRODUCTS





obagí for life


### TREATMENT PRODUCT VS. OTHER Rx PRODUCTS USED IN PAST





obagí for life

## TREATMENT PRODUCT VS. OTHER OTC PRODUCTS USED IN PAST





obagí for lífe

#### **SUBJECT PHOTOS**





OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

NSL, 002



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

NSL, 002



BASELINE DAY 14

OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MBM, 006



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MBM, 006



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MBM, 006



DAY 7 **BASELINE** 

OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD DMR, 009



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD



BASELINE DAY 84

OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MYW, 018



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MYW, 018



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

MYW, 018



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

DGV, 022



OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

DGV, 022



BASELINE DAY 84

OMP, INC. CLZ003 - SITE #1 LEONARD SWINYER, MD

DGV, 022

obagí for life

#### **CONCLUSIONS**

- Statistically significant reduction in lesions all time points
- Clinically visible signs reduction acne within 2 weeks
- Well tolerated (by week 2 mean erythema, peeling, dryness, stinging/burning, itching was between "none" and "mild")
- 81% subjects self assessed very satisfied or satisfied with their acne improvement
- 87% subjects self assessed regimen very effective or effective at Day 84 (82% at Day 28)
- 73% subjects self assessed very good or good acne improvement at Day 84 (82% at Day 28)
- Pump delivery problems Therapeutic Lotion and leaking Pore Therapy bottles impacted compliance

